PML case hits Genentech/Merck Serono's Raptiva
This article was originally published in Scrip
Executive Summary
Genentech's humanised monoclonal antibody drug Raptiva (efalizumab), approved as a treatment for psoriasis, has become the latest immunosuppressant product to be associated with progressive multifocal leucoencephalopathy (PML), the rare progressive demyelinating disease that usually leads to death or severe disability.